Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Edward T ...
RGX-202, a DMD gene therapy, has been well tolerated in an ongoing clinical trial and improved motor function for DMD boys, ...
The warning comes amid reports that unregulated therapies are being offered directly to patients, potentially illegally.
Clinical Trials Arena on MSN9h
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-oldThe interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...
ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase ...
Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...
Children with SMA given the gene therapy Zolgensma in infancy are maintaining motor milestones after up to 10 years, new ...
Satellos Bioscience Inc. ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today ...
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
A young man with Duchenne MD and treated with Elevidys has died of acute liver failure, Sarepta reports; it's working with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback